No connection

Search Results

ZLAB

BEARISH
$21.88 Live
Zai Lab Limited · NASDAQ
Target $34.84 (+59.2%)
$15.96 52W Range $44.34
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$2.47B
P/E
N/A
ROE
-22.6%
Profit margin
-38.1%
Debt/Equity
0.31
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ZLAB exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. While revenue growth remains positive at 17%, the company suffers from abysmal profitability with an operating margin of -54.40% and a surprisingly low gross margin of 10.47% for the biotech sector. The stark divergence between the 'Strong Buy' analyst consensus and the 0/100 technical trend, combined with consistent insider selling, suggests a speculative environment rather than a value-driven one. The long-term price trajectory (-87.4% over 5 years) confirms a sustained loss of investor confidence.

Key Strengths

Positive YoY revenue growth of 17.00%
Strong short-term liquidity with a Current Ratio of 2.45
Low leverage with a Debt/Equity ratio of 0.31
Positive YoY EPS growth (+42.5%), though still negative
Strong analyst support with a 'Strong Buy' consensus

Key Risks

Critical financial health deterioration (Piotroski F-Score 1/9)
Extremely low gross margins (10.47%) for a biotechnology firm
Persistent negative profitability (Profit Margin -38.15%)
Bearish insider sentiment with sales from CEO, CFO, and President
Severe long-term capital erosion (-87.4% 5-year return)
AI Fair Value Estimate
Based on comprehensive analysis
$18.5
-15.4% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
20
Weak
Value
30
Future
45
Past
15
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Operating Margins, Insider Selling, Technical Bearishness
Confidence
90%
Value
30/100

Trades at a premium P/S despite negative earnings and low gross margins.

Positives
  • Low Debt/Equity
Watchpoints
  • Negative P/E
  • High Price/Sales (5.37)
  • No Graham Number due to lack of earnings
Future
45/100

Growth is present in top-line revenue but not translating to the bottom line.

Positives
  • 17% Revenue Growth
  • High Analyst Target Price ($34.84)
Watchpoints
  • Failure to reach profitability
  • Negative Forward P/E
Past
15/100

Long-term historical performance is catastrophic.

Positives
  • Recent 1-month bounce (+25.2%)
Watchpoints
  • 5-year decline of 87.4%
  • Consistent earnings misses (1/4 last 4 quarters)
Health
10/100

Deterministic health scores indicate severe fundamental weakness.

Positives
  • Current Ratio 2.45
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE/ROA
Dividend
0/100

Non-dividend paying growth/speculative stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$21.88
Analyst Target
$34.84
Upside/Downside
+59.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ZLAB and closest competitors.

Updated 2026-04-23
ZLA
Zai Lab Limited
Primary
5Y
-87.4%
3Y
-39.1%
1Y
-34.9%
6M
-21.9%
1M
+25.2%
1W
-6.9%
LFS
LifeStance Health Group, Inc.
Peer
5Y
-70.8%
3Y
-18.8%
1Y
-5.5%
6M
+26.7%
1M
-3.6%
1W
+1.4%
RAR
Ultragenyx Pharmaceutical Inc.
Peer
5Y
-76.5%
3Y
-39.5%
1Y
-30.5%
6M
-24.0%
1M
+21.3%
1W
+6.5%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
XRA
DENTSPLY SIRONA Inc.
Peer
5Y
-80.0%
3Y
-68.7%
1Y
-7.0%
6M
-8.3%
1M
+3.8%
1W
-1.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-15.28
PEG Ratio
N/A
P/B Ratio
3.38
P/S Ratio
5.37
EV/Revenue
51.6
EV/EBITDA
-110.73
Market Cap
$2.47B

Profitability

Profit margins and return metrics

Profit Margin -38.15%
Operating Margin -54.4%
Gross Margin 10.47%
ROE -22.56%
ROA -12.16%

Growth

Revenue and earnings growth rates

Revenue Growth +17.0%
Earnings Growth N/A
Q/Q Revenue Growth +16.99%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.31
Low debt
Current Ratio
2.45
Strong
Quick Ratio
1.94
Excellent
Cash/Share
$0.62

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
51.2%
Op. Margin
-53.5%
Net Margin
-39.5%
Total Assets
$1.2B
Liabilities
$0.5B
Equity
$0.7B
Debt/Equity
0.64x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
105%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-26
$-0.46
-31.7% surprise
2025-11-06
$-0.33
-16.7% surprise
2025-08-07
$-0.37
+10.8% surprise

Healthcare Sector Comparison

Comparing ZLAB against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)
Return on Equity (ROE)
-22.56%
This Stock
vs
-92.94%
Sector Avg
-75.7% (Below Avg)
Profit Margin
-38.15%
This Stock
vs
-16.56%
Sector Avg
+130.4% (Superior)
Debt to Equity
0.31
This Stock
vs
2.75
Sector Avg
-88.6% (Less Debt)
Revenue Growth
17.0%
This Stock
vs
131.76%
Sector Avg
-87.1% (Slower)
Current Ratio
2.45
This Stock
vs
4.62
Sector Avg
-47.0% (Weaker)

Similar Companies

Peer comparison within the same industry

ZLAB Zai Lab Limited
BEARISH
Mkt Cap
$2.5B
P/E
-
ROE
-22.6%
Price
$21.88
LFST LifeStance...
NEUTRAL
Mkt Cap
$2.4B
P/E
320.0
ROE
0.7%
Price
$6.4
 Compare with ZLAB
RARE Ultragenyx...
BEARISH
Mkt Cap
$2.4B
P/E
-
ROE
-608.5%
Price
$24.81
 Compare with ZLAB
APLS Apellis...
BEARISH
Mkt Cap
$2.4B
P/E
105.2
ROE
7.5%
Price
$18.94
 Compare with ZLAB
XRAY DENTSPLY SIRONA Inc.
BEARISH
Mkt Cap
$2.4B
P/E
-
ROE
-36.4%
Price
$11.9
 Compare with ZLAB

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

AMADO RAFAEL
President
Sell
2026-04-06
2,739 shares · $56,007
SMILEY JOSHUA L
President
Sell
2026-04-06
3,017 shares · $61,692
DU YING SAMANTHA
Chief Executive Officer
Sell
2026-04-06
2,653 shares · $54,249
EDMONDSON FRAZOR TITUS III
Officer
Sell
2026-04-06
1,224 shares · $25,028
CHEN YAJING
Chief Financial Officer
Sell
2026-04-06
853 shares · $17,442
AMADO RAFAEL
Officer
Sell
2026-04-02
9,910 shares · $202,065
AMADO RAFAEL
Officer
Stock Award
2026-04-02
24,914 shares
SMILEY JOSHUA L
President
Sell
2026-04-02
9,614 shares · $196,029
SMILEY JOSHUA L
President
Stock Award
2026-04-02
39,207 shares
DU YING SAMANTHA
Chief Executive Officer
Sell
2026-04-02
5,576 shares · $113,695
DU YING SAMANTHA
Chief Executive Officer
Stock Award
2026-04-02
20,950 shares
EDMONDSON FRAZOR TITUS III
Officer
Sell
2026-04-02
4,194 shares · $85,516
EDMONDSON FRAZOR TITUS III
Officer
Stock Award
2026-04-02
22,290 shares
GAYNOR RICHARD BRIAN M.D.
Director
Buy
2026-03-17
1,731 shares · $32,733
AMADO RAFAEL
Officer
Sell
2026-03-13
2,957 shares · $55,083
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-02-26

Zealand Pharma A/S (ZLAB) filed an 8-K on February 26, 2026, likely to announce its annual financial results or earnings.

10-K
10-K
2026-02-26

ZLAB filed its annual 10-K report on February 26, 2026, providing comprehensive updates on its business operations and financial condition. The filing includes detailed financial analysis within the Management’s Discussion and Analysis section and outlines key operational risks in the Risk Factors section.

10-Q
10-Q
2025-11-06

ZLAB filed its 10-Q report on November 6, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-11-06

ZLAB filed an 8-K on November 6, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-10-16
10-Q
10-Q
2025-08-07

ZLAB filed its quarterly 10-Q report on August 7, 2025. While specific financial metrics were not provided in the excerpt, the filing includes a detailed section on risk factors under Item 1A.

8-K
8-K
2025-08-07

Zentalis Pharmaceuticals (ZLAB) filed an 8-K on August 7, 2025, likely to report its second-quarter financial results.

8-K
8-K
2025-06-18
10-Q
10-Q
2025-05-08

ZLAB filed its quarterly 10-Q report on May 8, 2025. The filing includes a section on risk factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-05-08

Zentalis Pharmaceuticals (ZLAB) filed an 8-K on May 8, 2025, likely to announce its first-quarter financial results.

DEF 14A
DEF 14A
2025-04-29
10-K
10-K
2025-02-27
8-K
8-K
2025-02-27
8-K
8-K
2025-01-03
8-K
8-K
2024-11-15
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
12 analysts
JP Morgan
2026-03-18
Maintains
Overweight Overweight
Cantor Fitzgerald
2026-02-27
Maintains
Overweight Overweight
JP Morgan
2026-02-05
Maintains
Overweight Overweight
UBS
2026-01-07
init
Buy

Past News Coverage

Recent headlines mentioning ZLAB from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile